Psychopharmacology

, Volume 76, Issue 4, pp 377–380 | Cite as

Serum neuroleptic concentrations and tardive dyskinesia

  • Dilip V. Jeste
  • Markku Linnoila
  • Richard L. Wagner
  • Richard Jed Wyatt
Original Investigations

Abstract

Using a liquid chromatographic assay, we measured serum neuroleptic concentrations in eight middle-aged or elderly female inpatients with tardive dyskinesia (TD) and eight controls. All 16 patients were receiving either thioridazine or mesoridazine at stable doses. TD patients were found to have a significantly higher ratio of serum concentration to daily dose of neuroleptics compared with controls. A 1-year follow-up revealed that this ratio did not change appreciably in those patients who continued to receive neuroleptics. Differences in serum neuroleptic levels were not related to peripheral inflammatory activity as indicated by serum α-1-acid glycoprotein concentrations. Of the various thioridazine metabolites, sulforidazine (which is reportedly the most potent in terms of affinity for dopaminergic and α-noradrenergic receptors) seemed to be significantly elevated in the serum of TD patients as compared with non-TD patients. Our data suggest a need for further pharmacokinetic investigations to study neuroleptic metabolism in patients with TD.

Key words

Tardive dyskinesia Neuroleptic Serum thioridazine concentration Serum glycoprotein 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bacher NM Lewis HA (1980) Low-dose propranolol in tardive dyskinesia. Am J Psychiatry 137:495–497Google Scholar
  2. Baldessarini RJ, Cole JO, Davis JM, Gardos G, Preskorn SH, Simpson GM, Tarsy D (1980) Tardive dyskinesia: Task force report. American Psychiatric Association, Washington D.C.Google Scholar
  3. Beyer WH (1966) Handbook of tables of probability and statistics. The Chemical Rubber Co., Cleveland, OhioGoogle Scholar
  4. Brandon S, McClelland HA, Protheroe C (1971) A study of facial dyskinesia in a mental hospital population. Br J Psychiatry 118:171–184Google Scholar
  5. Cohen BM, Herschel M, Aoba A (1979) Neuroleptic, antimuscarinic, and antiadrenergic activity of chlorpromazine, thioridazine, and their metabolites. Psychiatr Res 1:199–208Google Scholar
  6. Creese I, Synder SH (1977) A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood. Nature 270:180–182Google Scholar
  7. Freedman R, Kirch D, Bell J, Adler LE, Pecevich M, Pachtman E, Denver P (1982) Clonidine treatment of schizophrenia: Double-blind comparison to placebo and neuroleptic drugs. Acta Psychiat Scand 65:35–45Google Scholar
  8. Jeste DV, Wyatt RJ (1981) Changing epidemiology of tardive dyskinesia: An overview. Am J Psychiatry 138:297–306Google Scholar
  9. Jeste DV, Wyatt RJ (1982) Understanding and treating tardive dyskinesia. Guilford, New York (in press)Google Scholar
  10. Jeste DV, Rosenblatt JE, Wagner RL, Wyatt RJ (1979) High serum neuroleptic levels in tardive dyskinesia? N Engl J Med 301:1184Google Scholar
  11. Jeste DV, De Lisi LE, Zalcman S, Wise CD, Phelps BH, Rosenblatt JE, Potkin SG, Bridge TP, Wyatt RJ (1981) A biochemical study of tardive dyskinesia in young male patients. Psychiatr Res 4:327–331Google Scholar
  12. Jus A, Peneau R, Lachance R, Pelchat G, Jus K, Pires P, Villeneuve R (1976) Epidemiology of tardive dyskinesia. II. Dis Nerv Syst 37:257–261Google Scholar
  13. Kulik FA, Wilbur R (1980) Propranolol for tardive dyskinesia and extrapyramidal side effects (pseudoparkinsonism) from neuroleptics. Psychopharmacol Bull 16:18–19Google Scholar
  14. Mallya A, Jose C, Baig M, Williams R, Cho D, Mehta D, Volavka J (1979) Antiparkinsonics, neuroleptics and tardive dyskinesia. Biol Psychiatry 14:645–649Google Scholar
  15. Moreira MJC, Karnio IG (1979) Improvement of tardive dyskinesia with high doses of propranolol: A case report. Rev Paul Med 93:76–78Google Scholar
  16. Peroutka SJ, Synder SH (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 137:1518–1522Google Scholar
  17. Piafsky KM, Borga O, Odar-Cederlor I, Johansson C, Sjoqvist F (1978) Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma α-1-acid glycoprotein. N Engl J Med 26:1435–1439Google Scholar
  18. Rosenblatt JE, Pary RJ, Bigelow LB (1980) Measurement of serum neuroleptic concentrations by radioreceptor assay: Concurrent assessment of clinical response and toxicity. Psychopharmacol Bull 16:78–80Google Scholar
  19. Simpson GM, Kline NS (1976) Tardive dyskinesia manifestations, incidence, etiology and treatment. In: Yahr MD (ed) The basal ganglia. Raven, New YorkGoogle Scholar
  20. Simpson GM, Varga E, Lee JH, Zoubok B (1978) Tardive dyskinesia and psychotropic drug history. Psychopharmacology 58:117–124Google Scholar
  21. Skinner T, Gochnauer R, Linnoila M (1981) Liquid chromatographic method to measure thioridazine and its active metabolites in biological samples. Acta Pharmacol Toxicol (Copenh) 48:223–226Google Scholar
  22. Smith JM, Oswald WT, Kucharski LT, Waterman LJ (1978) Tardive dyskinesia: Age and sex differences in hospitalized schizophrenics. Psychopharmacology 58:207–211Google Scholar
  23. Viukari M, Linnoila M (1975) Effect of methyldopa on tardive dyskinesia in psychogeriatric patients. Curr Ther Res 18:417–424Google Scholar
  24. Viukari M, Linnoila M (1977) Effect of fusaric acid on tardive dyskinesia and mental state in psychogeriatric patients. Acta Psychiatr Scand 56:57–61Google Scholar
  25. Wyatt RJ (1976) Biochemistry and schizophrenia. IV. The neuroleptics, their mechanism of action: A review of the biochemical literature. Psychopharmacol Bull 12:5–50Google Scholar

Copyright information

© Springer-Verlag 1982

Authors and Affiliations

  • Dilip V. Jeste
    • 1
  • Markku Linnoila
    • 2
  • Richard L. Wagner
    • 1
  • Richard Jed Wyatt
    • 1
  1. 1.Adult Psychiatry Branch, Division of Special Mental Health Research, Intramural Research Program, National Institute of Mental HealthSaint Elizabeths HospitalWashington, D.C.USA
  2. 2.Clinical Psychobiology BranchNational Instittte of Mental HealthBethesdaUSA

Personalised recommendations